Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer

Cell Biochemistry and Biophysics

Volumn 71, Issue 2, 2015, Pages 1261-1265

  Wang, Feng ^a,b   Ning, Fangling ^b   Liu, Changmin ^b   Hao, Yanzhang ^b   Li, LiMian ^b   Yu, Zeshun ^b   Chen, Shaoshui ^b   Li, Baosheng ^a  

^a SHANDONG UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Brain metastases; Cisplatin; Gefitinib; Non small cell lung cancer; Three dimensional conformal radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; MELPHALAN; PREDNISOLONE; QUINAZOLINE DERIVATIVE; VINDESINE;

ADVERSE EFFECTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; PREDNISOLONE; QUINAZOLINES; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME; VINDESINE;

EID: 84925539431     PISSN: 10859195     EISSN: 15590283     Source Type: Journal    
DOI: 10.1007/s12013-014-0286-9     Document Type: Article

References (17)

1. Schouten, L., Rutten, J., Huveneers, H., & Twijnstra, A. (2002). Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer,94, 2698–2705.
2. Siker, M. L., & Mehta, M. P. (2007). Resection versus radiosurgery for patients with brain metastases. Future Oncology,3, 95–102.
3. Soffietti, R., Ruda, R., & Mutani, R. (2002). Management of brain metastases[J]. Journal of Neurology,249(1O), 1357–1369.
4. Postmus, P. E., Haaxma-Reiche, H., Smit, E. F., et al. (2000). Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with wholebrain radiotherapy-a phase III study of the European organization for the research and treatment of lung cancer cooperative group [J]. Journal of Clinical Ontology,18(19), 3400–3409.
5. Maemondo, M., Inoue, A., Kobayashi, K., et al. (2010). Gefitinib or chemot herapy for non-small-cell lung cancer with mutated EGFR [J]. New England Journal of Medicine,362(25), 2380–2388.
6. Zou, Y. M., Xiong, H., & Yu, S. Y. (2008). The effect of Gefitinib on the quality of life in patients with advanced non-small cell lung cancer[J]. China Oncology,18(12), 925–928.
7. Furuse, K., Kamimofi, T., kawahara, M., et al. (1997). A pilot study of concurrent w hole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastases[J]. British Journal of Cancer,75(4), 614–618.
8. Mckillop, D., Hutchison, M., Partridge, E. A., et al. (2004). Metabolic disposition of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibit or in rat, dog and m an[J]. Xenobiotica,34(10), 917–934.
9. Yan, D. F., Yan, S. X., Yang, J. S., et al. (2010). Hemrrhage of brain metastases from non- small cell lung cancer post Gefitinib therapy: two case reports and review of the literature[J]. BMC Cancer,10, 49.
10. Katz, A., & Zalewski, P. (2003). Quality-of-life benefits an devidence of antitumour activity for patients with brain metastases treated with Gefitinib[J]. British Journal of Cancer,89(Suppl 2), S15–S18.
11. Mckillop, D., Hutchison, M., Partridge, E. A., et al. (2004). Metabolic disposition of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor in rat, dog and man [J]. Xenobiotica,34(10), 917–934.
12. Fukuhara, T., & Sakakibara, T. (2008). Successful treatment of carcinomatous mengingitis with Gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene[J]. Tohoku Journal of Experimental Medicine,214(4), 359–363.
13. Wang, M.,Jing, Z., Min jiang, C.(2011). Cerebral penetration of Gefitinib inpatients with lung adenecarcinoma [J]. Journal of Clinical Oncology 29,(Supp1):a7608.
14. Villano, J. L., Maucer, A. M., & Vokes, E. E. (2003). A case study documenting the anticancer activity of ZD1839(Iressa) in the brain[J]. Annals of Oncology,14(4), 656–658.
15. Ceresoli, G. L., Cappuzzo, F., Gregorc, V., et al. (2004). Gefitinib in patients with brain metastases from non small cell lung cancer: a prospective trial [J]. Annals of Oncology,15(7), 1042–1047.
16. Wu, C., Li, Y. L., Wang, Z. M., et al. (2007). Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain [J]. Lung Cancer,57(3), 359–364.
17. Moran, C. (2011). Importance of molecular features of non-small cell lung cancer for choice of treatment[J]. American Journal of Pathology,178(5), 1940–1948.